Cargando…
Drotrecogin alfa (activated) ... a sad final fizzle to a roller-coaster party
Following the failure of PROWESS-SHOCK to demonstrate efficacy, Eli Lilly and Company withdrew drotrecogin alfa (activated) from the worldwide market. Drotrecogin was initially approved after the original trial, PROWESS, was stopped early for overwhelming efficacy. These events prompt consideration...
Autor principal: | Angus, Derek C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396243/ https://www.ncbi.nlm.nih.gov/pubmed/22309988 http://dx.doi.org/10.1186/cc11152 |
Ejemplares similares
-
Malaria vaccine roller coaster
por: Nkumama, Irene N., et al.
Publicado: (2021) -
When glycosylated hemoglobin is a true roller coaster
por: Peixoto, Fabiana Ribeiro, et al.
Publicado: (2018) -
Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis
por: Jamdar, Saurabh, et al.
Publicado: (2005) -
Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis
por: de Pont, Anne CJM, et al.
Publicado: (2009) -
3D Bioprinting: The Roller Coaster Ride to Commercialization
por: Elemoso, Anton, et al.
Publicado: (2020)